Potential risk factors associated with the use of cidofovir to treat benign human papillomavirus-related disease.

@article{Donne2009PotentialRF,
  title={Potential risk factors associated with the use of cidofovir to treat benign human papillomavirus-related disease.},
  author={Adam J Donne and Lynne Hampson and Xiaotong T He and Philip J. Day and Fiona Salway and Michael P. Rothera and Jarrod J. Homer and Ian Noel Hampson},
  journal={Antiviral therapy},
  year={2009},
  volume={14 7},
  pages={939-52}
}
BACKGROUND Cidofovir is currently being used off-licence to treat different viral infections, such as benign low-risk human papillomavirus (HPV)-related recurrent respiratory papillomatosis (RRP). There are concerns over the safety of this practice as rat studies demonstrated a high malignant transformation rate. As yet, there are no clinical reports of cidofovir-induced malignant changes in humans. METHODS Telomerase immortalised human keratinocytes (hTert) stably expressing E6 proteins from… CONTINUE READING